Ocean Biomedical, Inc. is a Providence, Rhode Island-based biopharma company with an innovative business model that accelerates the development and commercialization of scientifically compelling assets from research universities and medical centers. Ocean Biomedical deploys the funding and expertise to move new therapeutic candidates efficiently from the laboratory to the clinic to the world. Ocean Biomedical is currently developing five promising discoveries that have the potential to achieve life-changing outcomes in lung cancer, brain cancer, pulmonary fibrosis, and the prevention and treatment of malaria. The Ocean Biomedical team is working on solving some of the world’s toughest problems, for the people who need it most.
Company profile
Ticker
OCEAW, OCEA
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Aesther Healthcare Acquisition Corp., Ocean Biomedical, Inc./DE
SEC CIK
Corporate docs
IRS number
871309280
OCEAW stock data
Latest filings (excl ownership)
8-K
Entry into a Material Definitive Agreement
23 Jul 24
8-K
Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q
30 May 24
NT 10-Q
Notice of late quarterly filing
14 May 24
8-K
Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Annual Report on Form 10-K
24 Apr 24
10-Q
2023 Q3
Quarterly report
15 Apr 24
NT 10-K
Notice of late annual filing
1 Apr 24
8-K
Departure of Directors or Certain Officers
8 Mar 24
8-K
Departure of Directors or Certain Officers
4 Mar 24
Latest ownership filings
SC 13G
Ayrton Capital LLC
14 Feb 24
SC 13G/A
Lighthouse Investment Partners, LLC
14 Feb 24
SC 13G/A
ATW SPAC MANAGEMENT LLC
13 Feb 24
SC 13G/A
BOOTHBAY FUND MANAGEMENT, LLC
13 Feb 24
SC 13G/A
First Trust Capital Management L.P.
12 Feb 24
SC 13G/A
Polar Asset Management Partners Inc.
9 Feb 24
SC 13G/A
Saba Capital Management, L.P.
7 Feb 24
SC 13G/A
Weiss Asset Management LP
26 Jan 24
4
CHIRINJEEV KATHURIA
6 Oct 23
4
SURENDRA K AJJARAPU
24 Mar 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 1.00 mm | 1.00 mm | 1.00 mm | 1.00 mm | 1.00 mm | 1.00 mm |
Cash burn (monthly) | 33.33 k | 8.33 k | 885.00 k | 984.33 k | 376.67 k | 716.33 k |
Cash used (since last report) | 359.06 k | 89.77 k | 9.53 mm | 10.60 mm | 4.06 mm | 7.72 mm |
Cash remaining | 640.94 k | 910.23 k | -8.53 mm | -9.60 mm | -3.06 mm | -6.72 mm |
Runway (months of cash) | 19.2 | 109.2 | -9.6 | -9.8 | -8.1 | -9.4 |
Institutional ownership, Q2 2024
92.5% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 56 |
Opened positions | 44 |
Closed positions | 4 |
Increased positions | 4 |
Reduced positions | 3 |
13F shares | Current |
---|---|
Total value | 5.10 bn |
Total shares | 32.06 mm |
Total puts | 103.90 k |
Total calls | 483.01 k |
Total put/call ratio | 0.2 |
Largest owners | Shares | Value |
---|---|---|
Poseidon Bio | 22.84 mm | $0.00 |
Polar Asset Management Partners | 2.69 mm | $3.22 bn |
Aesther Healthcare Sponsor | 1.55 mm | $12.39 mm |
Vellar Opportunities Fund Master | 1.52 mm | $0.00 |
Vanguard | 406.53 k | $495.97 mm |
Fund Management B.V. Privium | 402.25 k | $19.27 mm |
Wolverine Asset Management | 305.60 k | $12.25 mm |
Walleye Capital | 228.02 k | $9.14 mm |
Boothbay Fund Management | 209.60 k | $255.72 mm |
MMCAP International Inc. SPC | 200.00 k | $8.02 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
2 Oct 23 | Chirinjeev Kathuria | Common Stock, par value $0.0001 | Other | Dispose J | Yes | No | 0 | 500,000 | 0.00 | 22,342,756 |
22 Mar 23 | Ajjarapu Surendra K | Common Stock, par value $0.0001 | Other | Dispose J | Yes | No | 0 | 1,050,000 | 0.00 | 315,000 |
28 Feb 23 | Ajjarapu Surendra K | Common Stock, par value $0.0001 | Other | Acquire J | Yes | No | 0 | 258,200 | 0.00 | 258,200 |
28 Feb 23 | Ajjarapu Surendra K | Common Stock, par value $0.0001 | Other | Acquire J | Yes | No | 0 | 469,300 | 0.00 | 469,300 |
28 Feb 23 | Ajjarapu Surendra K | Other | Dispose J | Yes | No | 0 | 2,625,000 | 0.00 | 1,365,000 | |
28 Feb 23 | Ajjarapu Surendra K | Private Placement Warrant Common Stock | Other | Acquire J | Yes | No | 11.5 | 1,291,000 | 14.85 mm | 1,291,000 |
28 Feb 23 | Ajjarapu Surendra K | Private Placement Warrant Common Stock | Other | Dispose J | Yes | No | 11.5 | 5,411,000 | 62.23 mm | 0 |
28 Feb 23 | Peterson Michael L | Other | Acquire J | No | No | 0 | 80,000 | 0.00 | 80,000 | |
28 Feb 23 | Peterson Michael L | Private Placement Warrant Common Stock | Other | Acquire J | No | No | 11.5 | 200,000 | 2.30 mm | 200,000 |
28 Feb 23 | Ajjarapu Surendra K | Common Stock, par value $0.0001 | Other | Acquire J | Yes | No | 0 | 21,252 | 0.00 | 21,252 |
Press releases
Ocean Biomedical (NASDAQ: OCEA) Congratulates Joint Venture Partner, Virion Therapeutics, on Positive Immunogenicity Results from Their Lead Checkpoint Modifier-Containing Immunotherapy, VRON-0200, for HBV Functional Cure, at EASL 2024
5 Jun 24
Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q
30 May 24